Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model
- 21 November 2016
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (1) , 81-89
Abstract
A government-funded trivalent influenza vaccine (TIV) program to prevent seasonal influenza was implemented in Taiwan since 1998. However, mismatch between the vaccine and circulating strains may occur. Alternatively, a quadrivalent influenza vaccine (QIV) includes all 4 influenza lineages could minimize the risk of mismatches. Therefore, QIV could be considered as an alternative strategy to enhance protection against seasonal influenza. The objective of the study was to analyze, from a governmental perspective, the cost-effectiveness of using QIV vs. TIV as a vaccination strategy in Taiwan. A lifetime multi-cohort, static Markov model was constructed with 9 age groups to assess the costs and effectiveness of QIV vs. TIV. Direct costs were obtained from a database released by the Ministry of Health and Welfare. Outcomes included life-years gained, quality-adjusted life years (QALYs) gained, influenza cases avoided and incremental cost-effectiveness ratios (ICERs). The discount rate of costs and effectiveness was set at 3.5% and the time horizon used in the model was 100 y. Results show that a vaccination strategy utilizing QIV instead of TIV would bring an additional 10,557 QALYs at an extra cost of US$39.4 million, yielding an ICER of US$3,015.07 per QALY gained. When setting the willingness-to-pay threshold at US$10,000, compared to TIV, the probability that QIV would be cost-effective was 98%. Sensitivity analyses show that ICER was sensitive to the changes of circulation of influenza virus subtypes and vaccine mismatch. From a governmental perspective, the QIV vaccination could be considered as a cost-effective strategy within the context of public health in Taiwan.Keywords
Funding Information
- GlaxoSmithKline (GSK) Far East B.V. Taiwan Branch
This publication has 29 references indexed in Scilit:
- Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong KongBMC Infectious Diseases, 2014
- Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United StatesHuman Vaccines & Immunotherapeutics, 2014
- Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysisBMC Medicine, 2013
- Surveillance and Vaccine Effectiveness of an Influenza Epidemic Predominated by Vaccine-Mismatched Influenza B/Yamagata-Lineage Viruses in Taiwan, 2011−12 SeasonPLOS ONE, 2013
- Re.: "Antibiotic exposure by 6 months and asthma and allergy at 6 years: findings in a cohort of 1,401 US children".American Journal of Epidemiology, 2011
- Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluationHealth Technology Assessment, 2009
- Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillationBMC Health Services Research, 2006
- Cost-effectiveness of influenza vaccination of healthy childrenVaccine, 2006
- The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of ageVaccine, 2006
- Systematic review and economic decision modelling for the prevention and treatment of influenza A and BHealth Technology Assessment, 2003